RMP
LTRN icon

Richards, Merrill & Peterson’s Lantern Pharma LTRN Stock Holding History

Richards, Merrill & Peterson’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-975
Closed -$3.45K – 353
2025
Q1 		$3.45K Hold
975
– – ﹤0.01% 451
2024
Q4 		$3.11K Buy
+975
New +$3.34K ﹤0.01% 448

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Richards, Merrill & Peterson's LTRN Position: Q2 2025 in Review

Richards, Merrill & Peterson sold out of Lantern Pharma (LTRN) in Q2 2025, closing a stake of 975 shares — an estimated $3.45K sold.

Richards, Merrill & Peterson first reported a position in LTRN in Q4 2024 and held it in 2 quarters. The position peaked at $3.45K in Q1 2025. 35 funds tracked by Wall St. Rank hold LTRN as of Q2 2025.

  • Richards, Merrill & Peterson reported no remaining Lantern Pharma position as of Q2 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 975 Lantern Pharma shares in Q2 2025, an estimated $3.45K.
  • Richards, Merrill & Peterson first reported a position in Lantern Pharma in Q4 2024 and held it in 2 quarters.
  • Richards, Merrill & Peterson's Lantern Pharma position peaked at $3.45K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.